Sally Church on Pharma Strategy Blog, today discusses personalized therapy for prostate cancer, and the extent to which this is possible?
Following the recent AACR special conference on the PI3K-mTor pathway, Sally shares some of the key learnings for oncology drug development and translational medicine.
Her opinion is that “in the future, targeted therapies may evolve in smaller subsets of disease with more logical or double or even triple combinations.”
In an insightful post on Pharma Strategy Blog, Sally discusses recent research that suggests there may be a market opportunity for anti-SPINK1 monoclonal antibodies that target a subset of prostate cancer patients. Breathtaking stuff!